LYMPHAZURIN Drug Patent Profile

When do Lymphazurin patents expire, and what generic alternatives are available?

Lymphazurin is a drug marketed by Covidien and is included in one NDA.

The generic ingredient in LYMPHAZURIN is isosulfan blue. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the isosulfan blue profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lymphazurin

A generic version of LYMPHAZURIN was approved as isosulfan blue by MYLAN INSTITUTIONAL on July 20^th, 2010.

Summary for LYMPHAZURIN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for LYMPHAZURIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Covidien	LYMPHAZURIN	isosulfan blue	SOLUTION;SUBCUTANEOUS	018310-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Summary
Lymphazurin (also known as Isosulfan Blue) is a diagnostic dye primarily used in lymphatic mapping procedures during oncologic surgeries. Its global market is defined by increasing cancer surgeries, growing adoption of sentinel lymph node biopsies, and an aging population. Investment potential hinges on market expansion, regulatory pathways, and emerging competitors. This report examines the current investment environment, market dynamics, and forecasted financial trajectories for Lymphazurin, emphasizing strategic considerations for stakeholders.

---

What is the Current Market for Lymphazurin?

Parameter	Details
Primary use	Lymphatic mapping in breast, melanoma, and other cancers
Regulatory status	FDA (U.S.), CE marking (EU), others
Market size (2022)	Estimated at USD 250-300 million globally
Key manufacturers	ASTA Medica (origin), Brevetti (Italy), pending generic entrants
Distribution channels	Hospitals, ambulatory surgical centers, specialty clinics

How Does the Market Size and Growth Potential Look?

Based on recent reports, the global radiopharmaceutical and diagnostic dye market, which includes Lymphazurin, is projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 5% from 2022–2027 [1]. The increasing rate of cancer surgeries, especially breast and melanoma cases, underscores expanding demand. The rising adoption of sentinel lymph node biopsies (SLNB) — a key use case for Lymphazurin — significantly boosts outlook.

What are the Market Drivers and Barriers?

Drivers	Barriers
Increasing global cancer incidence	Regulatory hurdles for new approvals
Adoption of minimally invasive, lymphatic mapping techniques	Competition from newer dyes and imaging agents
Aging population leading to more surgical interventions	Manufacturer supply constraints
Growing awareness in emerging markets	Cost considerations in developing regions

How does Lymphazurin compete versus alternative agents?

Agent	Advantages	Limitations	Market Share (Estimate)
Lymphazurin	Proven track record, familiarity	Limited imaging capability, risk of allergic reactions	70%
Indocyanine Green (ICG)	Near-infrared imaging, high sensitivity	Requires special equipment, higher costs	20%
Other agents (e.g., Patent Blue V)	Cost-effective, well-established	Less specific, higher adverse events	10%

What are the Regulatory and Patent Landscapes?

Lymphazurin is a well-established predicate device, existing under multiple regulatory approvals. As patent protections have largely expired, competition is driven by generic manufacturers. Recent regulatory reforms in the EU and U.S., emphasizing expedited reviews for diagnostic dyes, could impact market entry for new competitors.

Investment Scenario Analysis

Scenario	Assumptions	Market Impact	Financial Outlook (2025)
Optimistic	Increased adoption, new approvals, patent extensions	Market CAGR rose to 7%, new entrants expand share	USD 500 million revenue, 15% profit margins
Moderate	Steady growth in existing markets, slow approval process	CAGR remains at 5%, steady demand	USD 370 million revenue, 10–12% margins
Pessimistic	Regulatory delays, alternatives gaining ground	Flat or declining usage, market contraction	USD 250 million or less, margins decline

What is the Financial Trajectory for Lymphazurin?

Revenue Projections (USD Millions)

Year	Optimistic	Moderate	Pessimistic
2023	300	280	250
2024	400	330	250
2025	500	370	250

Profitability Outlook

Scenario	Operating Margins	Return on Investment	Key Factors
Optimistic	15–20%	ROI >10%	Market expansion, regulatory successes
Moderate	10–12%	ROI 7–9%	Stable demand, no significant disruption
Pessimistic	<10%	ROI <5%	Competition, regulatory hurdles

How Do Investors View Lymphazurin?

Investor Focus	Interest Rationale	Risks	Opportunities
Venture Capital	Growth in medical device and diagnostic segment	Regulatory delays, market saturation	Expansion into emerging markets, new indications
Pharmaceutical Companies	Diagnostic adjuncts, portfolio diversification	Competitive landscape, patent expiry	Licensing, strategic alliances

How Does Lymphazurin Compare to Market Alternatives?

Aspect	Lymphazurin	Indocyanine Green (ICG)	Patent Blue V
Detection Sensitivity	Variable, proven effective	High with near-infrared imaging	Moderate
Equipment Needed	Standard surgical tools	Specialized imaging equipment	Minimal
Cost	Lower	Higher	Lower
Regulatory Status	Regulated, well-established	Approved in many countries	Approved in some regions

What Regulatory and Market Entry Barriers Exist?

• Regulatory: Strict approval processes, need for validation of new uses
• Market: Established preferences for existing agents, potential for new dye development
• Manufacturing: Supply chain stability, quality standards
• Pricing: Reimbursement policies influence adoption

FAQs

Q1: What is the primary therapeutic application of Lymphazurin?
Lymphazurin is primarily used in sentinel lymph node biopsies for breast cancer, melanoma, and other malignancies to identify lymphatic pathways.

Q2: How does the market outlook for Lymphazurin look in emerging economies?
The growing prevalence of cancers and increasing surgical infrastructure in countries like India, China, and Brazil suggest a positive outlook, driven by expanding healthcare investment and adoption of sentinel lymph node procedures.

Q3: What are the entry barriers for new competitors in the Lymphazurin market?
Barriers include regulatory approval complexities, established market preferences, supply chain stability, and the need for clinical validation.

Q4: Could new dyes or imaging technologies replace Lymphazurin?
Yes. Agents such as Indocyanine Green and near-infrared imaging are gaining popularity due to higher sensitivity, though they require specialized equipment and may face adoption hurdles.

Q5: What legal or patent issues could impact Lymphazurin's market?
Most formulations are off-patent, leading to generic competition. Future developments or new indications could be subject to regulatory review or patent fishing by competitors.

---

Key Takeaways

• Market Drivers: Rising global cancer incidence and advances in minimally invasive surgical techniques propel demand for lymphatic mapping agents like Lymphazurin.
• Market Challenges: Competition from newer dyes, regulatory hurdles, and equipment costs pose risks; market entry in emerging regions remains promising.
• Financial Trajectory: The market is projected to grow moderately through 2025, with potential for higher growth if regulatory environments favor innovation and adoption accelerates.
• Investment Opportunities: Strategic alliances, geographic expansion, and development of adjunct imaging technologies could enhance financial returns.
• Strategic Consideration: Staying ahead requires monitoring regulatory changes, technological advancements, and competitor moves, particularly the adoption of near-infrared imaging agents.

---

References

Last updated: February 3, 2026

[1] MarketsandMarkets. (2022). Diagnostic Dyes Market by Product, Application, and Region.